XML 54 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurement (Details) - Recurring - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value $ 100,572 $ 7,455
Liabilities, fair value 14,241 16,244
Current portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 7,812 6,796
Current contingent liabilities-Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2] 2,602  
Current portion of co-promote termination liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [3]   322
Long-term portion of contingent liabilities - Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2] 1,355 3,652
Long-term portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 1,678 4,701
Liability for restricted investments owed to former licensees    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [4] 794 773
Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [5] 3,015  
Current portion of co-promote termination payments receivable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [3]   322
Short-term investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [6] 92,775 7,133
Notes Receivable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [7] $ 4,782  
Revenue volatility (percent) 65.00%  
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value $ 6,786 7,133
Liabilities, fair value 794 773
Quoted Prices in Active Markets for Identical Assets (Level 1) | Current portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Current contingent liabilities-Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2] 0  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Current portion of co-promote termination liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [3]   0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term portion of contingent liabilities - Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2] 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Liability for restricted investments owed to former licensees    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [4] 794 773
Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [5] 0  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Current portion of co-promote termination payments receivable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [3]   0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [6] 6,786 7,133
Quoted Prices in Active Markets for Identical Assets (Level 1) | Notes Receivable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [7] 0  
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 89,004 0
Liabilities, fair value 3,957 3,652
Significant Other Observable Inputs (Level 2) | Current portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 0 0 [8]
Significant Other Observable Inputs (Level 2) | Current contingent liabilities-Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2] 2,602  
Significant Other Observable Inputs (Level 2) | Current portion of co-promote termination liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [3],[8]   0
Significant Other Observable Inputs (Level 2) | Long-term portion of contingent liabilities - Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2] 1,355 3,652 [8]
Significant Other Observable Inputs (Level 2) | Long-term portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 0 0 [8]
Significant Other Observable Inputs (Level 2) | Liability for restricted investments owed to former licensees    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [4] 0 0 [8]
Significant Other Observable Inputs (Level 2) | Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [5] 3,015  
Significant Other Observable Inputs (Level 2) | Current portion of co-promote termination payments receivable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [3],[8]   0
Significant Other Observable Inputs (Level 2) | Short-term investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [6] 85,989 0 [8]
Significant Other Observable Inputs (Level 2) | Notes Receivable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [7] 0  
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 4,782 322
Liabilities, fair value 9,490 11,819
Significant Unobservable Inputs (Level 3) | Current portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 7,812 6,796
Significant Unobservable Inputs (Level 3) | Current contingent liabilities-Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2] 0  
Significant Unobservable Inputs (Level 3) | Current portion of co-promote termination liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [3]   322
Significant Unobservable Inputs (Level 3) | Long-term portion of contingent liabilities - Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2] 0 0
Significant Unobservable Inputs (Level 3) | Long-term portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 1,678 4,701
Significant Unobservable Inputs (Level 3) | Liability for restricted investments owed to former licensees    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [4] 0 0
Significant Unobservable Inputs (Level 3) | Current portion of co-promote termination payments receivable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [3]   322
Significant Unobservable Inputs (Level 3) | Short-term investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [6] 0 $ 0
Significant Unobservable Inputs (Level 3) | Notes Receivable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [7] $ 4,782  
[1] The fair value of the liabilities for CyDex contingent liabilities were determined based on the income approach using a Monte Carlo analysis. The fair value is subjective and is affected by changes in inputs to the valuation model including management’s assumptions regarding revenue volatility, probability of commercialization of products, estimates of timing and probability of achievement of certain revenue thresholds and developmental and regulatory milestones which may be achieved and affect amounts owed to former license holders and CVR holders. Changes in these assumptions can materially affect the fair value estimate.
[2] The liability for CVRs for Metabasis are determined using quoted market prices in an inactive market for theunderlying CVR.
[3] The co-promote termination payments receivable represents a receivable for future payments to be made by Pfizer related to product sales and is recorded at its fair value. The receivable and liability will remain equal. The fair value is determined based on a valuation model using an income approach.
[4] The liability for amounts owed to former licensees are determined using quoted market prices in active markets for the underlying investment received from a partner, a portion of which is owed to former licensees.
[5] Highly liquid investments with maturities less than 90 days from the purchase date are recorded as cash equivalents that are classified as Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.
[6] Investments in equity securities, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. Short-term investments in marketable securities with maturities greater than 90 days are classified as level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.
[7] The fair value of the convertible note receivable from Viking was determined using a probability weighted option pricing model using a lattice methodology. The fair value is subjective and is affected by certain significant input to the valuation model such as the estimated volatility of the common stock, which was estimated to be 65% at December 31, 2015. Changes in these assumptions may materially affect the fair value estimate.
[8] Adjusted to correct an error in disclosure that was deemed immaterial to the financial statements taken as a whole. Contingent liabilities related to Metabasis were reclassified from Level 1 to Level 2 as market is deemed inactive. Additionally, certain certificates of deposit with maturities less than 90 days were not previously disclosed in the table above.